Program
Dexamethasone
Also written as “dexamethasone”, “OTO-104” and “Dexycu”.
Its studies are mostly in Multiple Myeloma · Cataract · Macular Edema · Meniere Disease · Conjunctivitis, Allergic, led by 30 companies.
Drug pageDexamethasone: every studyMany companies study it; this page follows only the 92 they lead. All 1,797 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 200 open or running | phase 3since Mar 6, 2003 | Mar 6, 2003 | none ahead |
| Ocular Therapeutixits history only | 100 open or running | phase 3since Jan 9, 2014 | Jan 9, 2014 | none ahead |
| Takedaits history only | 100 open or running | phase 4since May 30, 2017 | Jul 25, 2007 | none ahead |
| Oculisits history only | 50 open or running | phase 3since Sep 2, 2021 | Oct 16, 2019 | none ahead |
| Sun Pharmaceutical Industriesits history only | 50 open or running | phase 3since Dec 19, 2007 | Dec 19, 2007 | none ahead |
| Oncotherapeuticsits history only | 40 open or running | phase 2since Aug 26, 2008 | Aug 26, 2008 | none ahead |
| EyePoint Pharmaceuticalsits history only | 30 open or running | phase 4since Dec 13, 2021 | Dec 13, 2021 | none ahead |
| Hamad Medicalits history only | 32 open or running | phase 3since Nov 30, 2020 | Jan 12, 2010 | none ahead |
| Sanofiits history only | 33 open or running | phase 2since Oct 20, 2020 | Oct 20, 2020 | Apr 1, 2027phase 2 · NCT06356571 |
| Alconits history only | 20 open or running | phase 4since Feb 29, 2008 | Feb 29, 2008 | none ahead |
| Azidus Brasilits history only | 20 open or running | phase 3since Apr 8, 2010 | Apr 8, 2010 | none ahead |
| iDropits history only | 20 open or running | phase 2since Sep 26, 2018 | Sep 26, 2018 | none ahead |
| Merckits history only | 20 open or running | phase 4since May 27, 2008 | Mar 17, 2008 | none ahead |
| NTC srlits history only | 20 open or running | phase 3since Nov 9, 2018 | Nov 6, 2018 | none ahead |
| Ocumension Therapeutics (Shanghai)its history only | 20 open or running | phase 4since Jun 20, 2024 | May 11, 2024 | none ahead |
| Quince Therapeuticsits history only | 20 open or running | phase 3since Jan 5, 2011 | Dec 3, 2010 | none ahead |
| Sanwa Kagaku Kenkyushoits history only | 20 open or running | phase 2since Mar 27, 2006 | Mar 27, 2006 | none ahead |
| Ascension Healthits history only | 10 open or running | phase 4since Aug 23, 2018 | Aug 23, 2018 | none ahead |
| Aurobindo Pharmaits history only | 10 open or running | phase 2since Sep 1, 2005 | Sep 1, 2005 | none ahead |
| Bunker Industria Farmaceutica Ltda.its history only | 10 open or running | phase 3since Jul 22, 2009 | Jul 22, 2009 | none ahead |
| Clinical Service, Chinaits history only | 10 open or running | phase 2since Mar 29, 2011 | Mar 29, 2011 | none ahead |
| Cochlearits history only | 11 open or running | no phasesince Sep 12, 2024 | Sep 12, 2024 | none ahead |
| Criteriumits history only | 10 open or running | phase 1since Aug 7, 2012 | Aug 7, 2012 | none ahead |
| Enceladus Pharmaceuticals BVits history only | 10 open or running | phase 2since Jan 3, 2017 | Jan 3, 2017 | none ahead |
| ICON Bioscienceits history only | 10 open or running | phase 3since Sep 9, 2015 | Sep 9, 2015 | none ahead |
| Laboratorios Sophia S.A de C.V.its history only | 11 open or running | phase 3since Jul 30, 2025 | Jul 30, 2025 | none ahead |
| Par Healthits history only | 10 open or running | phase 3since Jul 25, 2013 | Jul 25, 2013 | none ahead |
| Research Insightits history only | 10 open or running | phase 4since Apr 2, 2021 | Apr 2, 2021 | none ahead |
| Simcere Pharmaceutical Groupits history only | 10 open or running | phase 3since Sep 24, 2016 | Sep 24, 2016 | none ahead |
| Travanti Pharmaits history only | 10 open or running | phase 1since May 6, 2009 | May 6, 2009 | none ahead |
Also a collaborator on its studies: Karyopharm Therapeutics, AbbVie, Onyx Therapeutics, Abbott, Tigermed Consulting, Accelovance, ORA, Johnson & Johnson, Hoffmann-La Roche, Amgen, Novum Pharmaceutical Research Services, Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA and Prologue Research International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jan 5, 2011.
- Jun 1, 2021Early phase 1 study in HealthyOcular Therapeutix · NCT04945824 · 2 enrolled · United States
- Sep 2, 2021Phase 3 study in Diabetic Macular EdemaOculis · NCT05066997 · 552 enrolled · United States, Hong Kong, India and more
- Nov 24, 2021Phase 3 study in Inflammation Eye PainOculis · NCT05147233 · 241 enrolled · United States
- Dec 13, 2021EyePoint Pharmaceuticals’ first study: phase 4 study in CataractNew to EyePoint PharmaceuticalsEyePoint Pharmaceuticals · NCT05191706 · 17 enrolled · United States
- Sep 16, 20222 phase 3 studies in CataractEyePoint Pharmaceuticals · NCT05550363, NCT05550350
- Jan 20, 2023Phase 2 study in Multiple MyelomaSanofi · NCT05704049 · 118 enrolled · Australia, Brazil, China and more
- Aug 6, 2023Named dexamethasoneINNProposed as its International Nonproprietary Name in WHO's List 129 · before, OTO-104
- Nov 7, 2023Phase 3 study in Inflammation Eye PainOculis · NCT06128369 · 117 enrolled · United States
- Dec 7, 2023Phase 3 study in Diabetic Macular EdemaOculis · NCT06172257 · 401 enrolled · United States, Argentina, India and more
- Apr 5, 2024Phase 2 study in Plasma Cell Myeloma RefractorySanofi · NCT06356571 · 64 enrolled · United States
- May 11, 2024Ocumension Therapeutics (Shanghai)’s first study: phase 3 study in InflammationNew to Ocumension Therapeutics (Shanghai)Ocumension Therapeutics (Shanghai) · NCT06429306 · 285 enrolled · China
- Jun 20, 2024Phase 4 study in InflammationOcumension Therapeutics (Shanghai) · NCT06497699 · 263 enrolled · China
- Sep 12, 2024Cochlear’s first study: no phase study in Hearing LossNew to CochlearCochlear · NCT06598059 · 56 enrolled · United States
- Jul 30, 2025Laboratorios Sophia S.A de C.V.’s first study: phase 3 study in Cataract ExtractionNew to Laboratorios Sophia S.A de C.V.Laboratorios Sophia S.A de C.V. · NCT07305987 · 134 planned · Mexico
- Oct 26, 2026Primary completion moved from 2027-01-08 to 2027-04-01Date moved laterphase 2 · +3 months · NCT06356571
Ahead
- Apr 1, 2027Primary completion: phase 2 study in Plasma Cell Myeloma RefractorySanofi · NCT06356571
- Sep 13, 2027Primary completion: phase 2 study in Plasma Cell Myeloma RefractorySanofi · NCT04643002
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | Research Insight | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
| Triamcinolone Acetoniderule | clearside-biomedical-inc | phase 3 | 20 |
Studies
The newest 60 of 92 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07305987Cataract Extraction · Mexico | 3 | Recruiting | Laboratorios Sophia S.A de C.V. | Jun 30, 2026 | 134 |
| NCT06598059Hearing Loss · United States | – | Active, not recruiting | Cochlear | Feb 2, 2026 | 56 |
| NCT06497699Inflammation · China | 4 | Completed | Ocumension Therapeutics (Shanghai) | Jul 8, 2023 | 263 |
| NCT06429306Inflammation · China | 3 | Completed | Ocumension Therapeutics (Shanghai) | Nov 24, 2023 | 285 |
| NCT06356571Plasma Cell Myeloma Refractory · United States | 2 | Active, not recruiting | Sanofi | Apr 1, 2027 | 64 |
| NCT06172257Diabetic Macular Edema · United States, Argentina, India and more | 3 | Completed | Oculis | Apr 2, 2026 | 401 |
| NCT06128369Inflammation Eye Pain · United States | 3 | Terminated | Oculis | May 2, 2024 | 117 |
| NCT05704049Multiple Myeloma · Australia, Brazil, China and more | 2 | Active, not recruiting | Sanofi | Dec 22, 2025 | 118 |
| NCT05550363Cataract | 3 | Withdrawn | EyePoint Pharmaceuticals | Sep 2023 | 0 |
| NCT05550350Cataract | 3 | Withdrawn | EyePoint Pharmaceuticals | Sep 2023 | 0 |
| NCT05191706Cataract · United States | 4 | Terminated | EyePoint Pharmaceuticals | Aug 22, 2025 | 17 |
| NCT05147233Inflammation Eye Pain · United States | 3 | Completed | Oculis | Jun 22, 2023 | 241 |
| NCT05066997Diabetic Macular Edema · United States, Hong Kong, India and more | 3 | Completed | Oculis | Apr 10, 2026 | 552 |
| NCT04945824Healthy · United States | Early 1 | Terminated | Ocular Therapeutix | Nov 1, 2022 | 2 |
| NCT04911361Dry Eye Syndromes · United States | 4 | Completed | Research Insight | Dec 28, 2021 | 50 |
| NCT04654507Glomerulonephritis · Qatar | 3 | Recruiting | Hamad Medical | Dec 2023 | 120 |
| NCT04643002Plasma Cell Myeloma Refractory · United States, Australia, France and more | 2 | Recruiting | Sanofi | Sep 13, 2027 | 258 |
| NCT04711213Cataract in Inflammatory Ocular Disorders · El Salvador | 2 | Completed | iDrop | Oct 31, 2020 | 60 |
| NCT04539548Cataract · United States | 3 | Completed | Ocular Therapeutix | Dec 21, 2023 | 65 |
| NCT04130802Keratitis · United States | 2 | Completed | Oculis | Jan 31, 2020 | 153 |
| NCT04050865Conjunctivitis, Allergic · United States | 3 | Completed | Ocular Therapeutix | Feb 28, 2020 | 96 |
| NCT03739528Cataract · Italy | 3 | Completed | NTC srl | Dec 19, 2018 | 808 |
| NCT03740659Cataract · Italy | 2 | Completed | NTC srl | Dec 6, 2018 | 125 |
| NCT03687931Endophthalmitis · United States | 2 | Completed | iDrop | Feb 28, 2019 | 60 |
| NCT03646916Diabetes Mellitus · United States | 4 | Withdrawn | Ascension Health | Dec 31, 2020 | 0 |
| NCT03651128Multiple Myeloma · United States, Belgium, Canada and more | 3 | Completed | Bristol-Myers Squibb | Apr 13, 2026 | 386 |
| NCT03608501Multiple Myeloma · Brazil | 2 | Withdrawn | Takeda | Jun 30, 2021 | 0 |
| NCT03523221Anaphylaxis · Qatar | 1 | Recruiting | Hamad Medical | Dec 2024 | 210 |
| NCT03439293Multiple Myeloma · United States, Czechia, France and more | 2 | Completed | Takeda | Jan 1, 2022 | 61 |
| NCT03416374Relapsed and/or Refractory Multiple Myeloma · Japan | 4 | Completed | Takeda | May 28, 2021 | 45 |
| NCT03192150Inflammation · United States | 3 | Completed | Sun Pharmaceutical Industries | Nov 18, 2019 | 246 |
| NCT03192137Inflammation · United States | 3 | Completed | Sun Pharmaceutical Industries | Apr 17, 2019 | 260 |
| NCT03173092Multiple Myeloma · United States | 4 | Terminated | Takeda | Mar 30, 2026 | 141 |
| NCT03104270Multiple Myeloma · United States | 2 | Terminated | Oncotherapeutics | Oct 25, 2019 | 13 |
| NCT03033316Multiple Myeloma | 2 | Terminated | Enceladus Pharmaceuticals BV | Aug 2020 | 7 |
| NCT02988882Chronic Allergic Conjunctivitis | 3 | Completed | Ocular Therapeutix | Apr 27, 2016 | 86 |
| NCT02916420Multiple Myeloma · China | 3 | UNKNOWN | Simcere Pharmaceutical Group | Jun 2018 | 73 |
| NCT02917941Relapsed and/or Refractory Multiple Myeloma · Japan | 2 | Completed | Takeda | Aug 31, 2019 | 34 |
| NCT02736175Post-Surgical Ocular Pain | 3 | Completed | Ocular Therapeutix | May 2016 | 438 |
| NCT02547623Cataract · United States | 3 | Completed | ICON Bioscience | Aug 16, 2016 | 194 |
| NCT02468700Dry Eye Syndromes | 2 | Completed | Ocular Therapeutix | Aug 2015 | 43 |
| NCT02445326Chronic Allergic Conjunctivitis | 3 | Completed | Ocular Therapeutix | Aug 2015 | 73 |
| NCT02348528Multiple Myeloma · China | 2 | Completed | Bristol-Myers Squibb | Sep 29, 2016 | 65 |
| NCT02206425Multiple Myeloma · United States | 2 | Completed | Oncotherapeutics | Jan 19, 2018 | 45 |
| NCT02089113Post-Surgical Ocular Pain | 3 | Completed | Ocular Therapeutix | Jan 2015 | 241 |
| NCT02062905Chronic Allergic Conjunctivitis | 2 | Completed | Ocular Therapeutix | Aug 2014 | 68 |
| NCT02034019Pain · United States | 3 | Completed | Ocular Therapeutix | Dec 2014 | 247 |
| NCT02045017Multiple Myeloma · Austria, France, Germany and more | 2 | Completed | Bristol-Myers Squibb | Jan 27, 2017 | 81 |
| NCT02011113Multiple Myeloma · Japan | 2 | Completed | Bristol-Myers Squibb | Sep 2014 | 36 |
| NCT01946477Multiple Myeloma · United States, Canada, Japan and more | 2 | Completed | Bristol-Myers Squibb | Apr 30, 2025 | 186 |
| NCT01910155Otitis Externa · United States, Puerto Rico | 3 | Terminated | Par Health | Feb 2015 | 455 |
| NCT01891643Newly Diagnosed, Previously Untreated Multiple Myeloma · United States, Greece, Italy and more | 3 | Terminated | Bristol-Myers Squibb | Jun 25, 2020 | 23 |
| NCT01792102Multiple Myeloma · United States | 2 | UNKNOWN | Oncotherapeutics | Dec 2018 | 38 |
| NCT01698801Multiple Myeloma · Japan | 2 | Completed | Bristol-Myers Squibb | Nov 26, 2013 | 26 |
| NCT01660750Multiple Myeloma · United States | 1 | Completed | Criterium | Aug 2015 | 29 |
| NCT01593410Multiple Myeloma · China | 2 | Completed | Bristol-Myers Squibb | Jan 3, 2013 | 194 |
| NCT01575925Multiple Myeloma · United States, Canada | 1 | Completed | Bristol-Myers Squibb | Aug 7, 2018 | 25 |
| NCT01543490Motor Activity · United States | 3 | Completed | Sun Pharmaceutical Industries | Feb 4, 2020 | 558 |
| NCT01328236Leukemia, Plasma Cell · China | 2 | UNKNOWN | Clinical Service, China | Sep 2013 | 20 |
| NCT01277289Crohn Disease · Italy, Romania, Spain | 3 | Terminated | Quince Therapeutics | Dec 30, 2011 | 51 |
How it is read
Names in the registry
- “Dexamethasone”, 94 entries
- “dexamethasone”, 20 entries
- “OTO-104”, 9 entries
- “Dexycu”, 4 entries
- “Dexamethasone Oral”, 3 entries
Codes read as this program: OCS01.
Conditions, from the studies’ own filings
- Multiple Myeloma, 87 studies
- Cataract, 13 studies
- Macular Edema, 12 studies
- Meniere Disease, 8 studies
- Conjunctivitis, Allergic, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.